Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A flat illustration of a cargo container for pharmaceuticals

Jun 8, 2026

AI-driven monitoring cuts losses in pharma air cargo

AI technology is transforming pharmaceutical logistics by addressing critical visibility challenges that compromise temperature-sensitive shipments.A significant issue in the transportation of temperature-sensitive pharmaceuticals is the lack of real-time visibility, which often leads to product integrity risks. SkyCell's Pharma Monitoring platform aims to revolutionize this landscape by integrating predictive AI capabilities with live environmental tracking. This innovative approach allows for
A biotech product sample on a conference table with a research document in the background.

Jun 8, 2026

KOTRA, SK Biopharmaceuticals join forces to back 'K-bio' expansion in US

KOTRA and SK Biopharmaceuticals are collaborating to enhance the global footprint of South Korea's biotech sector, particularly in the U.S. market.This partnership aims to facilitate the expansion of domestic biotech companies into the United States, a crucial step as K-bio exports reached a historic $16.4 billion in 2025, highlighting the industry's increasing competitiveness on the global stage. The collaboration was formalized through a memorandum of understanding involving KOTRA, SK Biopharm
Tissue sample in a petri dish on a lab bench

Jun 7, 2026

If AI Healthcare Wins Big These Three Stocks Could Matter

The integration of artificial intelligence in healthcare is driving significant changes across various sectors, with three companies exemplifying this trend through their innovative applications.Tempus AI stands out as a healthcare technology firm utilizing a multimodal data platform to enhance cancer and genetic care. It generates approximately $1.36 billion in revenue, primarily from medical labs and research services. Tempus AI's partnerships with major pharmaceutical companies and its FDA-cl
A pill bottle with capsules on a wooden surface in a pharmacy setting.

Jun 7, 2026

How Oncology, Obesity and AI Diagnostics News At Roche Holding (SWX:ROP) Has Changed Its Investment Story

Roche Holding has made significant strides in oncology, obesity, and AI diagnostics, which may reshape its investment outlook.Recently, Roche and its subsidiaries have announced several key developments, notably the FDA's approval of FoundationOne CDx as a companion diagnostic for Genentech’s Itovebi regimen targeting specific breast cancer mutations. Additionally, the FDA has accepted a Priority Review for giredestrant, an oral SERD for early-stage ER-positive, HER2-negative breast cancer, and
A minimalist illustration of a pill representing pharmaceutical workflows.

Jun 7, 2026

Collate Raises $95 Million Series A To Expand AI Platform For Regulated Life Sciences Workflows

Collate has successfully secured $95 million in a Series A funding round to enhance its AI platform tailored for regulated workflows in the life sciences sector.The investment, led by prominent firms including Redpoint Ventures and Y Combinator, aims to bolster Collate's mission of providing reliable, patient-centric AI solutions for pharmaceutical and life sciences organizations. Founded by CEO Surbhi Sarna, Collate specializes in GxP-compliant software that automates and optimizes workflows wi
A Jelmyto drug vial on a lab countertop with supplies in the background.

Jun 7, 2026

Assessing UroGen Pharma (URGN) Valuation After Jelmyto Patent Settlement With Teva

UroGen Pharma (URGN) has recently gained attention following a settlement with Teva Pharmaceuticals regarding its cancer treatment, Jelmyto. This agreement not only clarifies the timeline for potential generic competition but also mitigates ongoing patent litigation risks.Despite this positive development, UroGen's stock has seen a slight decline, with recent returns showing an 8.67% drop over the last 30 days. However, the company has demonstrated significant long-term growth, boasting a remark
A glass slide with a mass spectrometry sample in a dimly lit laboratory setting.

Jun 7, 2026

Assessing Bruker (BRKR) Valuation After New FDA Claims And Mass Spectrometry Launches

Bruker Corporation (BRKR) is currently under scrutiny following its recent presentations at ASM Microbe 2026, where it highlighted new FDA-approved features for its MALDI Biotyper CA System, as well as advancements in diagnostics and ultra-high-resolution mass spectrometry.The company's stock has seen a decline of 6% in just one day and 4% over the past week, despite a significant 52% increase over the last three months. Bruker’s share price is currently around $56.39, which is slightly above on
Minimalist illustration of a mass spectrometry platform

Jun 7, 2026

What Waters (WAT)'s Diagnostics Wins and Q1 Beat Mean For Shareholders

Waters Corporation has reported a robust first quarter for 2026, showcasing a 20% increase in adjusted earnings per share and significant revenue growth, largely attributed to the early contributions from its recent acquisitions, BD Biosciences and Diagnostic Solutions.In addition to strong financial performance, Waters has made strides in its technology offerings, securing FDA 510(k) clearance for the BD BACTEC FXI Culture System. This system, along with the launch of two advanced mass spectrom
Flat design illustration of a quantum computer and fusion reactor

Jun 7, 2026

US–Japan $1 Billion Tech Alliance for AI, Quantum Computing, Fusion Energy, and Biotechnology

The United States and Japan have unveiled a significant $1 billion partnership aimed at fostering advancements in artificial intelligence, quantum computing, nuclear fusion, and biotechnology.This initiative marks a strategic shift towards integrated technological alliances among leading economies. It emphasizes coordinated research efforts, shared infrastructure, and closer collaboration between public institutions and private innovators. The focus on these technologies is driven by concerns ov
A minimalist representation of a drug compound in a flat design style.

Jun 7, 2026

Reid Hoffman’s Shift Spurs AI Biotech Innovation Wave

Reid Hoffman's recent transition from Microsoft to a more active role in AI-driven biotech signifies a notable shift in the industry landscape, particularly in the oncology sector.Hoffman's departure from Microsoft's board, announced in a recent filing, marks a strategic move back to his entrepreneurial roots. This change comes as he joins Manas AI, a biotech startup focused on leveraging artificial intelligence for drug discovery. With significant funding already secured, including a $50.6 mill
A vial of biologic solution on a laboratory countertop in a dimly lit setting.

Jun 6, 2026

Assessing ADMA Biologics (ADMA) Valuation After Legal Probes Short Seller Claims And Guidance Withdrawal

ADMA Biologics is currently facing significant challenges, including legal investigations and a critical report from short sellers, leading to a withdrawal of long-term guidance and a notable drop in stock price.The company has seen its shares decline by 20.9% in the past month and 55.4% year-to-date, despite a strong five-year total shareholder return. With ADMA's stock priced at $7.97, analysts have set an average target of $16.75, raising questions about whether the market is undervaluing fut
A minimalist representation of a medical device and software integration in flat design.

Jun 6, 2026

Moving from Hardware-Centric Systems to Software-as-a-Medical-Device (SaMD)

The healthcare landscape is experiencing a significant shift from hardware-centric systems to Software-as-a-Medical-Device (SaMD), driven by the increasing role of intelligent software in diagnostics.This transformation is particularly crucial in regions with a shortage of specialized medical professionals, such as India, where AI-powered SaMD solutions can automate real-time data analysis. This alleviates the pressure on scarce radiologists and cardiologists, enabling quicker clinical decision-